A carregar...
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
Immunotherapy is gathering momentum as a primary therapy for cancer patients. However, monotherapies have limited efficacy in improving outcomes and benefit only a subset of patients. Combination therapies targeting multiple pathways can augment an immune response to improve survival further. Here,...
Na minha lista:
| Publicado no: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
National Academy of Sciences
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4725491/ https://ncbi.nlm.nih.gov/pubmed/26729864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1510518113 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|